1 in 3 Americans are Not Up to Date
With Their Colorectal Cancer Screening.

How will you address your non-compliant patients? 

The Best Colorectal Cancer Test is the Test That Gets Done

ColonSentry® is a proprietary liquid biopsy test that uses advanced gene expression (mRNA) technology for the early identification of Colorectal Cancer (CRC). ColonSentry requires a simple, in-office blood draw. If the ColonSentry score is elevated in a patient at average risk, there is an increased probability the patient may have colorectal cancer. (4) 

​Blood tests have a greater than 95% in-office compliance rate that motivates patients to comply with CRC screening. (8)

ColonSentry Patient Selection Criteria
The American Cancer Society recommends that people at average risk of colorectal cancer start regular screening at age 45. ³
​
Patients may candidate for the ColonSentry Test if they are

• Age 45 of older and at average risk for Colorectal Cancer 
• Are without symptoms such as bleeding, abdominal pain, or change in bowel habits.
• Have not had a Colonoscopy or Stool-Based Screening Test

Enroll your practice by clicking the order test button below.

Enroll your practice

References

1. Liew CC, Ma J, Tang HC, et al. The peripheral blood transcriptome dynamically reflects system wide biology: a potential diagnostic tool. J Lab Clin Med. 2006  Mar;147(3):126-32. 
2. Marshall KW, Mohr S, Khettabi FE, et al. A blood-based biomarker panel for stratifying current risk for colorectal cancer. Int J Cancer. 2010 Mar 1;126(5):1177-86. 
3. American Cancer Society. Guideline for Colorectal Cancer Screening. Last revised May 30, 2018. 
4. Chao S, Ying J, Liew G, et al. Blood RNA biomarker panel detects both left- and right-sided colorectal neoplasms: a case- control study. J Exp Clin Cancer Res. 2013 Jul 23;32:44. 
5. Yip KT, Das PK, Suria D, et al. A case- controlled validation study of a blood- based seven-gene biomarker panel for colorectal cancer in Malaysia. J Exp Clin Cancer Res. 2010 Sep 16;29:128 
6. Han M, Liew CT, Zhang HW, et al. Novel blood-based, five-gene biomarker set for the detection of colorectal cancer. Clin Cancer Res. 2008 Jan 15;14(2):455-60. 
7. Moghadamyeghaneh Z, Alizadeh RF, Phelan M, et al. Trends in Colorectal Cancer Admissions and Stage at Presentation-Impact of Screening. Surgical endoscopy. 2016;30(8):3604-3610. doi:10.1007/s00464-015-4662-3.
8. Liles, E. et al.  Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. Cancer Treatment and Research Communications 10 (2017) 27–31.

---

The ColonSentry® Test is intended for use in patients without a personal history of colorectal cancer, pre-cancerous polyps or inflammatory bowel disease. The ColonSentry® test was developed and its performance characteristics were determined by StageZero Life Sciences. It has not been cleared or approved by the U.S. Food and Drug Administration. This test is for clinical purposes. It should not be regarded as investigational or for research. This laboratory is certified under CLIA as qualified to perform high complexity clinical laboratory testing.  The ColonSentry test must be ordered by and used only in consultation with a healthcare provider who can prescribe medications.